Skip to content

Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusion

Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusion - Safety and effectiveness of transdermal electrical stimulation for central retinal artery occlusion

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000036219
Enrollment
5
Registered
2019-04-01
Start date
2019-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central retinal artery occlusion

Interventions

Sponsors

Chiba university
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Clinically diagnosed with central retinal artery occlusion and age >20-years and <80-years. 2. Patients who have a definitive diagnosis of central retinal artery occlusion and have been older than 6 months since their estimated onset. 3. Patients with decimal visual acuity less than 0.7 above hand motion. 4. Patients who have obtained informed consent from the person's free will, after receiving sufficient explanation for participating in this clinical trial. 5. Patients who can visit hospital for 12 weeks every 2 weeks.

Exclusion criteria

Exclusion criteria: 1. Patients who have a history of drug allergy to drugs (mydriatics and anesthetics eye drops) to be used during the trial period. 2. Patients with complications that have a significant affect on visual function. 3. Patients with a history of or complications of malignancy. However, patients who have a history but have not relapsed for more than 5 years can be registered. 4. Patients diagnosed and treated for dementia and mental illness. 5. Patients complicated with poor control diabetes (HbA1c (NGSP)> 10.0%). 6. Patients with uncontrollable hypertension (systolic > 180 mmHg and / or diastolic 110 mmHg). 7. Patients with liver / renal dysfunction that falls under any of the following at clinical screening. AST, ALT: more than 3 times the upper limit of (facility) standard value Serum creatinine: more than 1.5 times the upper limit of (institutional) standard value 8. Patients taking ethambutol hydrochloride and / or amiodarone hydrochloride. 9. Patients who were pregnant, breastfeeding, may be or planned to be pregnant during the trial period. 10. Patients participating in other clinical trials. 11. Patients under investigational responsibility (shared) doctors judged inappropriate for participation in this trial.

Design outcomes

Primary

MeasureTime frame
logMAR visual acuity

Countries

Japan

Contacts

Public ContactGen Miura

Chiba university Department of ophthalmology and visual science

gmiura2@chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026